Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
chronic ascites as the initial presentation of systemic lupus erythematosus in a 37 year old syrian female patient a case report
Original title: “Chronic ascites as the initial presentation of systemic lupus erythematosus in a 37-year-old Syrian female patient: a case report.”
ras associated autoimmune leukoproliferative disorder manifesting in an adult patient as a lupus like syndrome and demonstrating bone marrow and peripheral blood findings reminiscent of chronic myelomonocytic leukemia
Original title: “Ras-Associated Autoimmune Leukoproliferative Disorder Manifesting in an Adult Patient as a Lupus-Like Syndrome and Demonstrating Bone Marrow and Peripheral Blood Findings Reminiscent of Chronic Myelomonocytic Leukemia.”
patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab interim analysis from the ongoing multicentre observational reveal study
Original title: “Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study.”
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.
Original title: “FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back”